Skip to main content
Firas Rahhal, MD, Ophthalmology, Beverly Hills, CA

FirasMRahhalMD

Ophthalmology Beverly Hills, CA

Retinal Disease

Vitreoretinal Surgery

Dr. Rahhal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Rahhal's full profile

Already have an account?

  • Office

    Retina Vitreous Associates Medical Group
    9001 Wilshire Blvd, Ste 301
    Beverly Hills, CA 90211
    Phone+1 310-854-6201

Education & Training

  • University of California (San Diego) Medical Center
    University of California (San Diego) Medical CenterFellowship, Surgical Retina and Vitreous, 1994 - 1996
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Ophthalmology, 1991 - 1994
  • Olive View/UCLA Medical Center
    Olive View/UCLA Medical CenterInternship, Internal Medicine, 1990 - 1991
  • Uconn School Of Medicine
    Uconn School Of MedicineClass of 1990
  • University of Pennsylvania
    University of PennsylvaniaBA, Biochemistry, 1982 - 1986

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1994 - 2025
  • NY State Medical License
    NY State Medical License 1991 - 2001
  • American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • The Retina Society
  • American Society of Retina Specialists
  • Fellow (FAAO) American Academy of Ophthalmology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Virtual Clinical Day Recap: Outlook Therapeutics Joined by Drs. Mark Humayun and Firas Rahhal to Discuss Need for FDA-Approved Ophthalmic Bevacizumab and Status of ONS-5010
    Virtual Clinical Day Recap: Outlook Therapeutics Joined by Drs. Mark Humayun and Firas Rahhal to Discuss Need for FDA-Approved Ophthalmic Bevacizumab and Status of ONS-5010May 27th, 2021
  • Virtual KOL Roundtable Recap: Outlook Therapeutics and Firas Rahhal, MD, Discussed Wet AMD Treatment Landscape and ONS-5010/LYTENAVA™
    Virtual KOL Roundtable Recap: Outlook Therapeutics and Firas Rahhal, MD, Discussed Wet AMD Treatment Landscape and ONS-5010/LYTENAVA™November 11th, 2020

Professional Memberships